Repurposing of FDA-approved drugs against cancer – focus on metastasis

Repurposing of FDA-approved drugs against cancer – focus on metastasis

Bibliographic Details
Main Authors:	Ozsvári, Béla, Lamb, Rebecca, Lisanti, Michael P.
Format:	Online
Language:	English
Published:	Impact Journals LLC 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925811/

Similar Items

Repurposing FDA-approved drugs for anti-aging therapies
by: Snell, Terry W., et al.
Published: (2016)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
by: Kim, Kevin, et al.
Published: (2015)

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
by: Zaidi, Asifa, et al.
Published: (2015)

Repurposing of approved cardiovascular drugs
by: Ishida, Junichi, et al.
Published: (2016)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
by: Benedict, Ashwini, et al.
Published: (2015)

Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
by: Li, Bin, et al.
Published: (2014)

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)
by: Fiorillo, Marco, et al.
Published: (2016)

Quantitative analysis on the characteristics of targets with FDA approved drugs
by: Sakharkar, Meena K., et al.
Published: (2007)

Quantitative analysis on the characteristics of targets with FDA approved drugs
by: Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar
Published: (2008-01-01)

FDA approved drugs as potential Ebola treatments
by: Ekins, Sean, et al.
Published: (2015)

QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
by: O’Reilly, Paul G., et al.
Published: (2016)

Why Did the FDA Approve These Advertisements?
by: Oaks, David
Published: (2006)

Larval Zebrafish Model for FDA-Approved Drug Repositioning for Tobacco Dependence Treatment
by: Cousin, Margot A., et al.
Published: (2014)

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
by: Panic, Gordana, et al.
Published: (2015)

Repurposing clinically approved cephalosporins for tuberculosis therapy
by: Ramón-García, Santiago, et al.
Published: (2016)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
by: Kesselheim, Aaron S., et al.
Published: (2016)

Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery
by: Colón, Jennifer M., et al.
Published: (2016)

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
by: Madrid, Peter B., et al.
Published: (2013)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
by: Mahajan, Rajiv
Published: (2013)

Exploring anti-malarial potential of FDA approved drugs: an in silico approach
by: Gayatri Ramakrishnan, et al.
Published: (2017-07-01)

Possible FDA-approved drugs to treat Ebola virus infection
by: Yuan, Shu
Published: (2015)

A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus
by: Ekins, Sean, et al.
Published: (2014)

Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi
by: Planer, Joseph D., et al.
Published: (2014)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
by: Alam, Md Tausif, et al.
Published: (2014)

US FDA food contact approvals boost
Published: (1999)

FDA-Approved Drugs that Protect Mammalian Neurons from Glucose Toxicity Slow Aging Dependent on Cbp and Protect Against Proteotoxicity
by: Lublin, Alex, et al.
Published: (2011)

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library
by: Feng, Jie, et al.
Published: (2014)

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
by: Vacchelli, Erika, et al.
Published: (2012)

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
by: Füzéry, Anna K, et al.
Published: (2013)

Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
by: Hou, Zhi-Jie, et al.
Published: (2015)

Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity
by: Bhat-Nakshatri, Poornima, et al.
Published: (2013)

Systematic Repurposing Screening in Xenograft Models Identifies Approved Drugs with Novel Anti-Cancer Activity
by: Roix, Jeffrey J., et al.
Published: (2014)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
by: Michael M. Boyiadzis, et al.
Published: (2018-05-01)

Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells
by: Taylor, David J, et al.
Published: (2011)

Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library
by: Pascoalino, Bruno S., et al.
Published: (2016)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
by: Constantine, Ginger D., et al.
Published: (2016)

Thalamotomy for essential tremor: FDA approval brings brain treatment with FUS to the clinic
by: Paul S. Fishman
Published: (2017-07-01)

Plasma preparation to measure FDA-approved protein markers by selected reaction monitoring
by: Kiseleva, Olga I., et al.
Published: (2015)

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease
by: Lamb, Rebecca, et al.
Published: (2015)

Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection
by: Veljkovic, Veljko, et al.
Published: (2015)